Oikawa T, Hasegawa M, Morita I, Murota S, Ashino H, Shimamura M, Kiue A, Hamanaka R, Kuwano M, Ishizuka M
Division of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Japan.
Anticancer Drugs. 1992 Jun;3(3):293-9. doi: 10.1097/00001813-199206000-00014.
We found recently that 15-deoxyspergualin, an analog of spergualin, which is an antibiotic and includes a spermidine moiety in its structure, exhibits anti-angiogenic activity. We have now carried out in vitro experiments with bovine vascular endothelial cells to determine which events occurring during angiogenesis are affected by this microbial angiogenesis inhibitor. 15-Deoxyspergualin did not inhibit the production of urokinase-type plasminogen activator (u-PA) or type IV collagenase by vascular endothelial cells. The direct inhibition of u-PA activity by 15-deoxyspergualin was not observed either. The angiostatic antibiotic neither affected the migration of vascular endothelial cells nor inhibited the endothelial cell proliferation in a two-dimensional culture system. We also examined the effect of 15-deoxyspergualin on the proliferation of endothelial cells in a three-dimensional culture system involving collagen gel, in which cell growth resembles more closely the endothelial cell proliferation during in vivo angiogenesis than that in a two-dimensional culture system without collagen gel. The antibiotic inhibited cell proliferation in a dose-dependent manner, indicating that the three-dimensional culture system is useful for finding a new angiogenesis inhibitor with a different mode of action from those of angiogenesis inhibitors found by using a two-dimensional assay system; however, no cause-effect relationship has yet been established. Taken together, these results suggest the possible involvement of the inhibition of vascular endothelial cell growth by 15-deoxyspergualin in its angiogenesis-inhibitory effect. 15-Deoxyspergualin appears to be a promising candidate as an angiogenesis inhibitor for controlling aberrant angiogenic responses occurring in different states, including tumor development.(ABSTRACT TRUNCATED AT 250 WORDS)
我们最近发现,15-脱氧精胍菌素,一种精胍菌素的类似物,它是一种抗生素,其结构中包含一个亚精胺部分,具有抗血管生成活性。我们现在已经用牛血管内皮细胞进行了体外实验,以确定血管生成过程中发生的哪些事件会受到这种微生物血管生成抑制剂的影响。15-脱氧精胍菌素不会抑制血管内皮细胞产生尿激酶型纤溶酶原激活剂(u-PA)或IV型胶原酶。也未观察到15-脱氧精胍菌素对u-PA活性的直接抑制作用。这种血管生成抑制性抗生素既不影响血管内皮细胞的迁移,也不抑制二维培养系统中的内皮细胞增殖。我们还研究了15-脱氧精胍菌素对三维胶原凝胶培养系统中内皮细胞增殖的影响,在该系统中细胞生长比无胶原凝胶的二维培养系统更类似于体内血管生成过程中的内皮细胞增殖。这种抗生素以剂量依赖性方式抑制细胞增殖,这表明三维培养系统有助于发现一种作用方式与二维检测系统中发现的血管生成抑制剂不同的新型血管生成抑制剂;然而,尚未建立因果关系。综上所述,这些结果表明15-脱氧精胍菌素抑制血管内皮细胞生长可能参与了其血管生成抑制作用。15-脱氧精胍菌素似乎是一种有前途的血管生成抑制剂候选物,可用于控制在包括肿瘤发展在内的不同状态下发生的异常血管生成反应。(摘要截短至250字)